Physicians' Academy for Cardiovascular Education

Three SGLT2 inhibitors associated with decreased CVD risk in real-world setting

Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic)

A multinational observational analysis

Literature - Birkeland KI, Jørgensen ME, Carstensen B, et al. - Lancet Diabetes Endocrinol 2017; epub ahead of print

Main results

Conclusion

In a real-world clinical setting, new use of an SGLT2 inhibitor was associated with a decreased CVD and CV mortality risk compared with the new use of other glucose-lowering drugs in diabetic patients. This is consistent with results of CV outcome trials of drugs in this class. Moreover, as more than 90% of SGLT2 inhibitor exposure time was contributed by dapagliflozin, the finding lend support for a possible class effect, as findings were complementing to what has previously been shown in CV outcome trials with empagliflozin and canagliflozin. These findings could be useful for health-care practitioners treating diabetic patients at high CVD risk.

References

Show references

Find this article online at Lancet Diabetes Endocrinol

Share this page with your colleagues and friends: